58 related articles for article (PubMed ID: 9572489)
1. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
[TBL] [Abstract][Full Text] [Related]
2. TUBB3 overexpression has a negligible effect on the sensitivity to taxol in cultured cell lines.
Tame MA; Manjón AG; Belokhvostova D; Raaijmakers JA; Medema RH
Oncotarget; 2017 Sep; 8(42):71536-71547. PubMed ID: 29069726
[TBL] [Abstract][Full Text] [Related]
3. The nature of the modification at position 37 of tRNAPhe correlates with acquired taxol resistance.
Pan Y; Yan TM; Wang JR; Jiang ZH
Nucleic Acids Res; 2021 Jan; 49(1):38-52. PubMed ID: 33290562
[TBL] [Abstract][Full Text] [Related]
4. Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells.
White CM; Martin BK; Lee LF; Haskill JS; Ting JP
Cancer Immunol Immunother; 1998 Apr; 46(2):104-12. PubMed ID: 9558006
[TBL] [Abstract][Full Text] [Related]
5. Elucidating mechanical transition effects of invading cancer cells with a subnucleus-scaled microfluidic serial dimensional modulation device.
Mak M; Reinhart-King CA; Erickson D
Lab Chip; 2013 Feb; 13(3):340-8. PubMed ID: 23212313
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of new immortalized human breast cell lines.
Iype LE; Michael M; Verma M; Iype PT
Cytotechnology; 1998; 26(3):207-18. PubMed ID: 9618944
[TBL] [Abstract][Full Text] [Related]
7. Understanding drugs in breast cancer through drug sensitivity screening.
Uhr K; Prager-van der Smissen WJ; Heine AA; Ozturk B; Smid M; Göhlmann HW; Jager A; Foekens JA; Martens JW
Springerplus; 2015; 4():611. PubMed ID: 26543746
[TBL] [Abstract][Full Text] [Related]
8. [
Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Cells Transition from Mesenchymal to Amoeboid Migration in Tunable Three-Dimensional Silk-Collagen Hydrogels.
Khoo AS; Valentin TM; Leggett SE; Bhaskar D; Bye EM; Benmelech S; Ip BC; Wong IY
ACS Biomater Sci Eng; 2019 Sep; 5(9):4341-4354. PubMed ID: 31517039
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cantharidin toxicity in breast cancer cells to two common chemotherapeutics.
Kern KM; Schroeder JR
Int J Breast Cancer; 2014; 2014():423059. PubMed ID: 25302124
[TBL] [Abstract][Full Text] [Related]
11. The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines.
Arman K; Ergün S; Temiz E; Öztuzcu S
Mol Biol Rep; 2014 Dec; 41(12):8031-6. PubMed ID: 25189649
[TBL] [Abstract][Full Text] [Related]
12. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
[TBL] [Abstract][Full Text] [Related]
13. Development of peptide nucleic acid probes for detection of the HER2 oncogene.
Metaferia B; Wei JS; Song YK; Evangelista J; Aschenbach K; Johansson P; Wen X; Chen Q; Lee A; Hempel H; Gheeya JS; Getty S; Gomez R; Khan J
PLoS One; 2013; 8(4):e58870. PubMed ID: 23593123
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
Corcoran C; Rani S; O'Brien K; O'Neill A; Prencipe M; Sheikh R; Webb G; McDermott R; Watson W; Crown J; O'Driscoll L
PLoS One; 2012; 7(12):e50999. PubMed ID: 23251413
[TBL] [Abstract][Full Text] [Related]
15. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
Campone M; Noël B; Couriaud C; Grau M; Guillemin Y; Gautier F; Gouraud W; Charbonnel C; Campion L; Jézéquel P; Braun F; Barré B; Coqueret O; Barillé-Nion S; Juin P
Mol Cancer; 2011 Sep; 10():110. PubMed ID: 21899728
[TBL] [Abstract][Full Text] [Related]
16. Testing for HER2 in Breast Cancer: A Continuing Evolution.
Shah S; Chen B
Patholog Res Int; 2010 Dec; 2011():903202. PubMed ID: 21188214
[TBL] [Abstract][Full Text] [Related]
17. EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.
Nautiyal J; Kanwar SS; Majumdar AP
Curr Protein Pept Sci; 2010 Sep; 11(6):436-50. PubMed ID: 20491625
[TBL] [Abstract][Full Text] [Related]
18. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.
Hawthorne VS; Huang WC; Neal CL; Tseng LM; Hung MC; Yu D
Mol Cancer Res; 2009 Apr; 7(4):592-600. PubMed ID: 19372587
[TBL] [Abstract][Full Text] [Related]
19. Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.
Kashentseva EA; Douglas JT; Zinn KR; Curiel DT; Dmitriev IP
J Mol Biol; 2009 May; 388(3):443-61. PubMed ID: 19285990
[TBL] [Abstract][Full Text] [Related]
20. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.
Nakayama S; Torikoshi Y; Takahashi T; Yoshida T; Sudo T; Matsushima T; Kawasaki Y; Katayama A; Gohda K; Hortobagyi GN; Noguchi S; Sakai T; Ishihara H; Ueno NT
Breast Cancer Res; 2009; 11(1):R12. PubMed ID: 19239702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
